Biotech Stocks Healthcare Stocks Life Sciences Small Caps Stocks Undervalued Stocks

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics' suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer…

ByNick Sundich

28

May 2025

Biotech Stocks Healthcare Stocks Market news Mid Cap Stocks News Small Caps Stocks

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

2025 has been, and will continue to be, a big year for Proteomics, which has just launched PromarkerD onto the Australian market. Before this year is over, the company anticipates…

ByNick Sundich

21

Jan 2025

Healthcare Stocks

Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them

There aren't many ASX stocks fighting diabetes, but the few that are have a big market opportunity ahead of them. And they are not just about fighting the condition directly but…

ByNick Sundich

12

Dec 2024

Healthcare Stocks Life Sciences Small Caps Stocks

Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!

Proteomics (ASX:PIQ) is one of the healthcare stocks to watch in CY25, because it has not one, not two, but three diagnostic tests to be commercialised in Australia, the USA and…

ByNick Sundich

13

Sep 2024

Healthcare Stocks Mid Cap Stocks News Penny Stocks Small Caps Stocks

The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!

The Pitt Street Research Life Sciences Conference is happening on September 19, 2024! The Life Sciences sector in Australia and New Zealand continues to mature in 2024. In spite…

ByNick Sundich

28

Aug 2024

Healthcare Stocks

Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?

Proteomics International Laboratories (ASX:PIQ) is one of the larger companies that will be presenting at next month's Life Sciences Conference. Capped at over $100m, its flagship product is PromarkerD, a…

ByNick Sundich

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them

Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!

The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!

Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here